APVO Aptevo Therapeutics Inc.

0.65
-0.03  -4%
Previous Close 0.68
Open 0.68
Price To Book 1.12
Market Cap 29,517,539
Shares 45,279,244
Volume 394,273
Short Ratio
Av. Daily Volume 385,721
Stock charts supplied by TradingView

NewsSee all news

  1. Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

    APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead Sciences, Takeda

  2. Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

    SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food

  3. Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

    SEATTLE and LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience

  4. Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

    Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and

  5. Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

    Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development terminated - noted November 14, 2018.
APVO414
Castration-resistant prostate cancer
Development terminated - noted November 14, 2018.
Otlertuzumab
Relapsed or refractory peripheral T-cell lymphoma
Phase 1 data from higher cohorts due in next several months.
APVO436
Acute myeloid leukemia (AML)
Development terminated - noted October 3, 2019.
APVO210
Healthy volunteers

Latest News

  1. Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

    APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead Sciences, Takeda

  2. Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

    SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food

  3. Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

    SEATTLE and LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience

  4. Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

    Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and

  5. Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

    Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo

  6. Aptevo Therapeutics Provides Corporate and Pipeline Update

    Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study;Evidence of Potential Clinical Activity

  7. Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

    New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith Potential to Enhance Anti-Tumor Immune Response